Kornimate/medical-research-clean huggingface dataset:
dyslexics' visual attention field

Conditions: Dyslexia

Summary: dyslexia is often considered like a phonological deficit but some researches show that a visual attention (v-a) deficit can occur in dyslexia. the investigator want to show that some dyslexics have a reduced v-a field in visual search when the investigator use separable feature (letter-like). if the investigator demonstrate that, he will show that v-a deficit can be transpose to an ability acquired before reading, the visual search. therefore, the v-a deficit can't be a consequence of reading problem but a cause of it for some dyslexics. the investigator could imagine an earlier diagnosis for children at risk to develop dyslexia and make reeducation more specific for the deficit observed.


Eligibility criteria:
inclusion criteria: * normal or corrected to normal vision * diagnosed dyslexics with a recent "alouette" test exclusion criteria: * other developmental problem (dysphasia, dyspraxia, adhd) * strabismus, amblyopia, oculomotor paralysis

Keywords: dyslexia visual fields visual attention span visual search visual attention field
evaluating alternative aftercare models for ex-offenders

Conditions: Drug/Substance Abuse/Addiction; Alcohol Abuse/Addiction

Summary: this study is examining the relative effects of alternative aftercare models for ex-offenders who are recovering from substance abuse/addiction. the study is a longitudinal, randomized field trial that assigns participants to one of three conditions: oxford house, a professionally-run residential treatment facility, or a control condition that involves usual aftercare chosen by participants (which may include no treatment at all). oxford houses are self-run residential recovery homes based on the premise of mutual support. these homes do not involve professional treatment staff and the expenses (e.g. rent, utilities) are paid for by the residents. the hypothesis of this study is that oxford house participants will have as good or better outcomes in terms of substance recovery, recidivism, and health in comparison to the participants who were assigned to the residential treatment facility, and better outcomes in comparison to the control group. in addition, the cost to government/tax payers will be substantially lower given that participants pay their own way.


Eligibility criteria:
inclusion criteria: * released from prison/jail in last 24 months * recovering from alcohol or drug dependence exclusion criteria: * convicted of violent crime such as murder, aggravated assault * currently using alcohol or drugs

Keywords: oxford house recovery substance abuse alcohol abuse addiction
concordance between mini-mental stats examination (mmse) and an adapted version of the mmse in reunion island population (mms-run)

Conditions: Neurocognitive Deficit

Summary: illeteracy concerns more than 38% of réunion island's people older than 65 years old, which makes it an important risk factor for dementia and a limit to neurocognitive test's administration. the mmsrun is a mini mental state examination's version adapted to illeteracy and réunionese culture, inspired by hindi mental state examination's work. it allows a way better participation during neurocognitive evaluation, but it has never been validated. this study is a peliminary study to a validation, where the concordance between scores obtained from mmsrun and from the consensual version of mini mental state examination proposed by greco (groupe de réflexion sur les evaluations cognitives) - the only french version validated - on a hospitalized and eldery population will be analyzed.


Eligibility criteria:
inclusion criteria: * patient who needs a cognitive evaluation by mmse/mms-run during usual medical care * patient born and living in réunion island * patient hospitalized in geriatrics department or in the departement of physical medecine and rehabilitation * patient who agrees to participate in the study and who does not oppose to the use of his data exclusion criteria: * patient with hearing and visual disorder that can interfere in cognitive test administration * patient with altered state of consciousness (glasgow score different of 15) * patient diagnosed or having symtoms compatible with a psychiatric pathology with psychosis (altered perception of reality) * patient with a current and severe addiction to alcohol or any other drug (smoking excluded) * patient deprived of liberty by judicial or administrative decision and patient under curatorship or guardianship

Keywords: neurocognitive deficit neurocognitive impairment major neurocognitive disorder dementia geriatric senior illeteracy : mini mental state examination eldery
an efficacy and safety study of itraconazole sequential therapy (intravenous injection followed by oral solution) in invasive pulmonary fungal infections

Conditions: Pulmonary Fungal Infection

Summary: the purpose of this study is to evaluate the efficacy and safety of itraconazole sequential therapy (intravenous injection/oral solution) in participants with invasive pulmonary fungal infections (\[ipfi\]; lung diseases caused by fungal infection).

this is an open-label (all people know the identity of the intervention), single arm, multicenter (when more than one hospital or medical school team work on a medical research study) study to evaluate the efficacy and safety of itraconazole sequential therapy in participants with ipfi. the study duration will be 4 to 6 weeks. the treatment will be divided into the intravenous (into a vein) injection period and the oral solution administration (giving) period. during the intravenous injection period 200 milligram (mg) twice daily loading dose (large initial dose) will be given for first 2 days, 200 mg once daily for the subsequent 12 days. then sequential itraconazole oral solution 200 mg twice daily will be given as maintenance therapy (treatment designed to help the original primary treatment to succeed) for 2-4 weeks. participant's clinical, mycological and comprehensive efficacy will be assessed at week 6. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * probable or proven invasive pulmonary infectious participants (ipfi) - hospitalized participants (at least hospitalized treatment and observation could be ensured during the intravenous injection period) - the participants (or legal representatives) have signed the informed consent forms. exclusion criteria: * currently taking taboo drugs, such as terfenadine, astemizole, cisapride and hmg coa reductase inhibitors (for example simvastatin, lovastatin, oral or intravenous midazolam or triazolam) - history of allergy or intolerance to imidazoles or pyrrole drugs (for example fluconazole, itraconazole, ketoconazole, miconazole, clotrimazole) - pregnant and breast feeding women, or women of child bearing age not taking effective contraception measures - participants with pure oral, urinary tract, and vaginal candidiasis (yeast infection) - participants with fungal meningitis (inflammation of the meninges), active liver disease, renal insufficiency with the serum creatinine clearance rate less than 30 milliliter per minute (ml/min), and current abnormal cardiac function such as congestive heart failure (condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body), or participants with history of congestive heart failure

Keywords: invasive pulmonary fungal infection itraconazole
efficacy of different treatment regimens with chitosan-n- acetylcysteine in moderate-to-severe dry eye disease

Conditions: Eye Diseases

Summary: aim of this pilot study is to evaluate the best treatment regime of chitosan-n-acetylcysteine (lacrimera®) compared to preservative-free, hyaluronic-acid containing eyedrops (hylo-vision® sine).

the present pilot study seeks to investigate the best fitting treatment regime of moderate-to-severe ded with c-nac compared to preservative-free, hyaluronic-acid containing eyedrops (hylo-vision® sine) by applying a randomized, prospective, adaptive, controlled design.

Eligibility criteria:
inclusion criteria: * age older than 22 years * corneal staining (marked to severe; nei grading scale \>=10) exclusion criteria: * usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-a) * usage of systemic antibiotic therapy * any pathology of the ocular surface except dry eye disease (e.g. corneal scarring, cornea ectasia) * ocular surgery within prior 3 months to screening * preceding refractive corneal surgery (e.g. lasik) * ocular injury within prior 3 months * ocular herpes of eye or eyelid within prior 3 months * active ocular infection * active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months * eyelid abnormalities that affect lid function * ocular surface abnormality that may compromise corneal integrity * pregnancy and nursing women (in women of childbearing age a pregnancy test will be performed before inclusion into the study)
a study to evaluate the efficacy and safety of intravitreal ksi-301 compared with intravitreal aflibercept in participants with neovascular (wet) age-related macular degeneration (wamd)

Conditions: Wet Age-related Macular Degeneration

Summary: this phase 3 study will evaluate the efficacy and safety of ksi-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wamd)

this is a phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of ksi-301 5 mg in participants with visual impairment due to treatment-naïve neovascular (wet) age-related macular degeneration (wamd) the primary endpoint will be assessed as an average of weeks 40, 44, and 48; additional secondary endpoints for efficacy will be assessed by visit over time

Eligibility criteria:
inclusion criteria: * signed informed consent prior to participation in the study. * treatment-naïve choroidal neovascularization (cnv) secondary to amd. * bcva etdrs score between 83 and 25 letters, inclusive, in the study eye. * decrease in vision in the study eye determined by the investigator to be primarily the result of wamd. * other protocol-specified inclusion criteria may apply exclusion criteria: * bcva of hand motion or worse in the non-study eye or non-physical presence of a non-study eye (i.e., monocular). * active or suspected ocular or periocular infection or inflammation. * cnv secondary to other causes in the study eye. * any history or evidence of a concurrent ocular condition present in the study eye, that in the opinion of the investigator could require either medical or surgical intervention or affect macular edema or alter visual acuity during the study. * uncontrolled glaucoma in the study eye. * significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of safety, oct or fundus photography. * cataract in the study eye that in the judgment of the investigator is expected to require surgical extraction within 12 months of screening. * women who are pregnant or lactating or intending to become pregnant during the study. * recent history (within the 6 months prior to screening) of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure or any acute coronary event. * history of a medical condition that, in the judgment of the investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product. * uncontrolled blood pressure defined as a systolic value ≥180 mmhg or diastolic value ≥100 mmhg while at rest. * other protocol-specified exclusion criteria may apply

Keywords: amd wet amd neovascularization secondary to age-related macular degeneration ksi-301 aflibercept vascular endothelial growth factor vegf anti-vegf antibody biopolymer conjugate macular degeneration wamd retinal degeneration retinal diseases eye diseases vision disorders vision, low kodiak
effect of isocaloric ketogenic diet on physical performance at high altitude

Conditions: Ketogenic Dieting; Altitude Hypoxia; Physical Activity

Summary: a ketogenic diet (kd) reduces daily carbohydrates (chos) ingestion by replacing most calories with fat. kd is of increasing interest among athletes because it may increase their maximal oxygen uptake (vo2max), the principal performance limitation at high altitudes. the investigators examined the tolerance of a 4-week isocaloric kd (ickd) under simulated hypoxia and the possibility of evaluating ickd performance benefits with a maximal graded exercise bike test under hypoxia and collected data on the effect of the diet on performance markers and arterial blood gases.

in a randomised single-blind cross-over model, 6 recreational mountaineers (age 24 to 44 years) will complete a 4-week ickd followed or preceded by a 4-week habitual mixed western diet (hd). performance parameters (vo2max, lactate threshold \[lt\], peak power \[ppeak\]) and arterial blood gases (pao2, paco2, ph, hco3-) will be measured at baseline under two conditions (normoxia and hypoxia) as well as after a 4-week hd and 4-week ickd under the hypoxic condition.

Eligibility criteria:
inclusion criteria: * recreational mountaineers * familiarity with altitude (\>2500 m above sea level) and males/females 20 to 45 years old. exclusion criteria: * high training load (such as professional athletes) or new planned training * dietary restrictions.
digoxin drug-drug interaction with lurasidone hcl

Conditions: Schizophrenia

Summary: the objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.


Eligibility criteria:
inclusion criteria: * male and female 18 to 65 years of age * bmi \>= 19.5 and \<= 37 kg/m2 * no clinically relevant abnormal laboratory values exclusion criteria: * history or presence of renal or hepatic insufficiency * participated in a clinical trial in the past 30 days * use of con meds that prolong the qt/qtc taken within 28 days prior to study drug administration

Keywords: lurasidone schizophrenia latuda
functional mri to assess brain damage in cardiac arrest patients

Conditions: Cardiac Arrest; Brain Injuries

Summary: this is a single-center, observational study. patients after successful cardiopulmonary resuscitation (cpr) will be transferred to the emergency intensive care unit for further standardized management. after successful return of spontaneous circulation (rosc) for 72h and hemodynamics remained stable for 24h, the post-resuscitated patients underwent functional magnetic resonance imaging (fmri) examination. during the examination, the supervising physician accompanied the patient and monitored the patient's vital signs using a magnetic resonance monitoring system (siemens healthcare prism, germany). patients who are on ventilators are mechanically ventilated using a magnetic ventilator (hamilton-mri, usa). in additional to conventional sequences, fmri is performed for diffusion-prepared pseudo-continuous arterial spin labeling (dp-pcasl) and blood oxygenation level dependent functional magnetic resonance imaging (bold-fmri). these mri sequences allow quantitative assessment of the patients' cerebral microcirculation, blood-brain barrier, and cerebral oxygenation status. patients will be followed up for neurologic prognosis according to the modified rankin scale (mrs) at 6 months after disease onset.


Eligibility criteria:
inclusion criteria: * age ≥18 years. * sustained hemodynamic stability for ≥24h. * the patients were unconscious and not able to obey verbal commands. * advanced life support and target temperature management within 6 hours of return of spontaneous circulation (rosc). exclusion criteria: * patients with hemodynamic instability. * patients who could not complete cranial mri examination for special reasons. * patients during pregnancy. * patients who combined traumatic brain injury, stroke, cerebral hemorrhage and other diseases. * patients whose family members did not agree to be enrolled.

Keywords: cardiac arrest functional magnetic resonance imaging cerebral microcirculation blood-brain barrier cerebral oxygenation
effects of early treadmill training on ambulatory ability in stroke patients: electromyographic and kinematic analyses

Conditions: Stroke

Summary: the purpose of this study is to explore an alternative approach that emphasizes task specificity and treadmill training for ambulation training of these patients.

restoration of independent ambulatory ability is one of the most common functional goals of patients with hemiplegia after stroke. ambulation training, therefore, is an important part of physical therapy intervention for these patients. conventional neurologic physical therapy for ambulation training, based sorely on neurophysiology, prohibits early ambulation experience after stroke in attempt to avoid the development of abnormal gait patterns. such an approach has been shown to be limited in helping these patients regain independent ambulatory ability.

Eligibility criteria:
inclusion criteria: * between 40 and 75 years old * first stroke with r't side hemiplegia due to middle cerebral artery occlusion and received acute treatment at ntuh * being willing to sign an informed consent approved by the human subjects committee of the national taiwan university hospital * able to ambulate independently in parallel bars and having no independent ambulation ability outside parallel bars excursion criteria: * having unstable vital sign, unconsciousness, or obvious cognitive, perception, and language impairment, and couldn't communicate with the experimenters * having other neurological diseases, or moderate to severe neuromuscular or musculoskeletal or cardiovascular disorders, or disorders from systematic diseases other than stroke

Keywords: stroke hemiplegia gait ambulation training neurologic physical therapy
bioequivalence of ethylenediamine dihydrochloride study

Conditions: Allergic Contact Dermatitis

Summary: the purpose of this study is to compare the allergen ethylenediamine dihydrochloride when prepared using methylcellulose versus preparation using polyvinylpyrrolidone.

we propose an open, prospective, single-site study to evaluate the bioequivalence of ethylenediamine dihydrochloride in methylcellulose (mc)and polyvinylpyrrolidone (pvp) formulations. bioequivalence will be determined in minimum of 15 adult subjects, with a clinical history of contact dermatitis and a positive patch test (current or previous) to ethylenediamine ("sensitives").

Eligibility criteria:
inclusion criteria: * current or previous symptoms and/or history consistent with allergic contact dermatitis, and positive patch test (within the past 10 years) to ethylenediamine dihydrochloride * 18 years of age or older, otherwise in good health * female subjects of childbearing potential must consent to a urine pregnancy test; results must be negative for study inclusion. * informed consent signed and understood by each subject. exclusion criteria: * subjects unable to meet inclusion requirements * women who are breastfeeding or pregnant * topical treatment during the last 7 days with corticosteroids or other immunosuppressive agents on or near the test area * systemic treatment during the last 7 days with corticosteroids (equivalent to \> 10 mg prednisone) or other immunosuppressive agents * treatment with ultraviolet (uv) light (including tanning) during the previous 3 weeks * acute dermatitis outbreak or dermatitis on or near the test area on the back * subjects unable to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting test panels from excess moisture due to showering or vigorous activity) * subject participation in clinical trials of investigational drugs, treatments, or devices, other than t.r.u.e. test, during this study or 3 weeks prior to inclusion in this study

Keywords: ethylenediamine dihydrochloride
corticosteroids+5-aminosalicylic acid compared to corticosteroids in the treatment of moderate-severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the role of steroids in the treatment of ulcerative colitis (uc) is well established, and recommended by professional societies. however, there are no data investigating whether the addition and/or continuation of 5-aminosalicylic agents as combination therapy with systemic corticosteroids is superior to corticosteroids alone in patients with moderate-severe active uc. thus, in practical terms, the decision regarding 5-aminosalicylic (to add or continue), on top of steroids treatment, is taken on an arbitrary basis. the aim of this study is to compare the efficacy of steroids alone vs combination of steroids + 5-aminosalicylic in the treatment of moderate-severe uc exacerbation.

he role of steroids in the treatment of ulcerative colitis (uc) is well established, and recommended by professional societies. however, there are no data investigating whether the addition and/or continuation of 5-aminosalicylic agents as combination therapy with systemic corticosteroids is superior to corticosteroids alone in patients with moderate-severe active uc. thus, in practical terms, the decision regarding 5-aminosalicylic (to add or continue), on top of steroids treatment, is taken on an arbitrary basis. the aim of this study is to compare the efficacy of steroids alone vs combination of steroids + 5-aminosalicylic in the treatment of moderate-severe uc exacerbation.

Eligibility criteria:
inclusion criteria: * uc known and diagnosed by established clinical-endoscopic and histological criteria or newly-diagnosed uc, based on clinical and endoscopic findings, and about to start treatment with corticosteroids. * current hospitalization with severe ulcerative colitis exacerbation as defined by a lichtiger score of \>10 * age \>18 * if taking thiopurines, the dose must be stable for 2 months prior to admission exclusion criteria: * pregnant women * allergy/unable to take study medications * active infection * severe renal/liver/cardiorespiratory condition * toxic megacolon or signs of imminent colectomy * treatment with an anti-tumor necrosis factor in 3 months prior to admission * prior treatment with cyclosporin or tacrolimus * alcohol dependancy * unwilling/ unable to give an informed consent * participation in clinical trials in the last 2 months prior to admission
inbone total ankle arthroplasty(taa)using calcaneal stem fixation

Conditions: Arthrodesis; Degenerative Arthritis; Rheumatoid Arthritis; Complications; Arthroplasty, Mechanical

Summary: the primary objective of this study is to evaluate the radiographic outcomes of total ankle arthroplasty in patients having a calcaneal stem.

the primary objective of this study is to determine the radiographic outcomes of patients who have received taa with the calcaneal stem. due to the fixation of the stem in the calcaneus, talar component position, osteolysis and bone quality are of interest to the fda. specifically, subsidence and/or migration of the talar component, osteolysis as a measure of wear, and bone quality of the talus, cuboid and navicular are to be evaluated in this study. therefore, the radiographic outcomes of this study aim to assess these parameters

Eligibility criteria:
inclusion criteria: patients who will be recruited for participation in this study received the taa with calcaneal stem between december 6, 2005 and november 13, 2007 at approximately 28 sites. exclusion criteria: patients who will be recruited for participation in this study received the taa with calcaneal stem between december 6, 2005 and november 13, 2007 at approximately 28 sites.

Keywords: total ankle arthroplasty